Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
Abstract
Background and aims: The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance therapy.
Citations
Altmetric:
Date
2022-08
Type
Article
Subject
Gastroenterology
Collections
Citation
J Crohns Colitis . 2022 Aug 30;16(8):1222-1234
Journal / Source Title
Journal of Crohn's and Colitis
DOI
10.1093/ecco-jcc/jjac030
PMID
35239968
Publisher
Oxford University Press
Publisher’s URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426670/